Cargando…

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy

Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas. Autologous CAR-T cells require patient-specific manufacturing and thus exte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruppel, Katharina Eva, Fricke, Stephan, Köhl, Ulrike, Schmiedel, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971283/ https://www.ncbi.nlm.nih.gov/pubmed/35371071 http://dx.doi.org/10.3389/fimmu.2022.822298

Ejemplares similares

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

CAR T cells take centre stage
por: Beavis, Paul A, et al.
Publicado: (2019)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Production and Application of CAR T Cells: Current and Future Role of Europe
por: Vucinic, Vladan, et al.
Publicado: (2021)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
por: Walcher, Lia, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B
por: Feigl, Frederik Fabian, et al.
Publicado: (2023)

CAR T-cells for colorectal cancer immunotherapy: Ready to go?
por: Ghazi, Bouchra, et al.
Publicado: (2022)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021)

CAR-NK Cells: From Natural Basis to Design for Kill
por: Khawar, Muhammad Babar, et al.
Publicado: (2021)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjsr255ln2vc3q97as97p1kmrr